“We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required regulatory approvals. We also plan to produce the drug’s active pharmaceutical ingredient (API) in-house helping its cost effectiveness and consistent availability,” Jubilant Life Sciences chairman Shyam Bhartia and managing director Hari S Bhartia mentioned in a press release.
ET had reported on May 5 that Gilead Sciences was in talks with a number of Indian firms together with Jubilant Life Sciences for a licensing deal.
Jubilant additionally has the precise to obtain a know-how switch of Gilead Sciences’ manufacturing course of to scale up manufacturing to allow expedited entry of the medication to Covid-19 sufferers upon approvals by regulatory authorities in respective nations.
Remdesivir is among the most watched medication for the remedy of coronavirus. In April it obtained an emergency approval from the US Food and Drug Administration (USFDA), making it the primary authorised remedy for the virus. The USFDA’s approval was primarily based on trial outcomes which confirmed that the drug lowered the restoration time to 5 days from 10 days for reasonable sufferers.
Gilead Sciences is in talks with different Indian firms for related licensing agreements, ET has learnt.
